Crystal deal tombstone marking a follow-on offering by life sciences company Intelligent Bio Solutions The design incorporates the firm’s drug screening cartridge. (23AJH030)
Crystal deal tombstone marking a follow-on offering by life sciences company Intelligent Bio Solutions The design incorporates the firm’s drug screening cartridge. (23AJH030)
Crystal commemorative marking a licensing and commercialization agreement between Corbus Pharmaceuticals and CSPC Pharmaceutical Group. The agreement centers on a potential treatment for tumors associated with lung, breast, and prostate cancers. (23AZH089)
Lucite tombstone recognizing a registered direct offering by BioCardia. The Sunnyvale, California-based company develops cellular and cell-derived therapeutics for cardiovascular and pulmonary conditions. (23AKL286)
Custom Lucite with an embedded drug vial commemorating FDA approval of ELAHERE. Developed by ImmunoGen, the drug was granted accelerated FDA approval as a treatment for ovarian cancer. (23AKL266)
Diamond-shaped crystal deal toy commemorating a follow-on stock offering by Swiss biotech firm Oculis. (23AKL262)
Lucite commemorative marking the first patient dosed in a clinical study involving LunAIRo. Developed by Apnimed, the drug is intended for the treatment of obstructive sleep apnea. (23AZH173)
Custom Award recognizing contributions to the development of a medical implant, and embedding the actual device within Lucite. (23AZH106)
Crystal tombstone celebrating a favorable verdict in an antitrust action against Gilead Sciences. The claim had centered on an earlier patent settlement involving Gilead and Teva. (23AKL380)
